Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background and Purpose Non-small cell lung cancer (NSCLC) tumours are mostly heterogeneous. We hypothesized that areas within the tumour with a high pre-radiation 18F-deoxyglucose (FDG) uptake, could identify residual metabolic-active areas, ultimately enabling selective-boosting of tumour sub-volumes. Material and Methods Fifty-five patients with inoperable stage I-III NSCLC treated with chemo-radiation or with radiotherapy alone were included. For each patient one pre-radiotherapy and one post-radiotherapy FDG-PET-CT scans was available. Twenty-two patients showing persistent FDG-uptake in the primary tumour after radiotherapy were analyzed. Overlap-fractions (OF) were calculated between standardized uptake value (SUV) threshold-based auto-delineations on the pre- and post-radiotherapy scan. Results Patients with residual metabolic-active areas within the tumour had a significantly worse survival compared to individuals with a complete metabolic response (p=0.002). The residual metabolic-active areas within the tumour largely corresponded (OF>70%) with the 50%SUV high FDG-uptake area of the pre-radiotherapy scan. The hotspot within the residual area (90%SUV) was completely within the GTV (OF=100%), and had a high overlap with the pre-radiotherapy 50%SUV threshold (OF>84%). Conclusions The location of residual metabolic-active areas within the primary tumour after therapy corresponded with the original high FDG-uptake areas pre-radiotherapy. Therefore, a single pre-treatment FDG-PET-CT scan allows for the identification of residual metabolic-active areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., & Ariyoshi, Y. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2692 · Cited by 1,495 · cited 2×
“Although the prognosis has improved, in locally advanced non-small cell lung cancer (NSCLC), the 5-year survival is 20% at best [2–7].”
BackgroundEffects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., Nijs, A., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260805 · Cited by 1,277 · cited 1×
“As the improved long-term survival with concurrent chemo-radiation compared to sequential chemotherapy and radiotherapy is due to improved local tumour control, strategies to increase local tumour control are warranted [6–8].”
BackgroundPositron emission tomography provides molecular imaging of biological processes
Phelps, M. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.16.9226 · Cited by 1,229
THE INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS
Wambersie, A. (2004) · Journal of the ICRU · doi:10.1093/jicru/ndh019 · Cited by 869
van Meerbeeck, J. P., Kramer, G. W. P. M., Van Schil, P. E. Y., Legrand, C., Smit, E. F., Schramel, F., Tjan-Heijnen, V. C., Biesma, B., Debruyne, C., van Zandwijk, N., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk093 · Cited by 705 · cited 1×
“Although the prognosis has improved, in locally advanced non-small cell lung cancer (NSCLC), the 5-year survival is 20% at best [2–7].”
BackgroundFournel, P., Robinet, G., Thomas, P., Souquet, P.-J., Léna, H., Vergnenégre, A., Delhoume, J.-Y., Le Treut, J., Silvani, J.-A., Dansin, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.070 · Cited by 542 · cited 3×
“Although the prognosis has improved, in locally advanced non-small cell lung cancer (NSCLC), the 5-year survival is 20% at best [2–7].”
BackgroundVansteenkiste, J. F., Stroobants, S. G., Dupont, P. J., De Leyn, P. R., Verbeken, E. K., Deneffe, G. J., Mortelmans, L. A., & Demedts, M. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3201 · Cited by 439
Theragnostic imaging for radiation oncology: dose-painting by numbers
Bentzen, S. M. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)01737-7 · Cited by 416
Sample size tables for exact single‐stage phase II designs
A'Hern, R. P. (2001) · Statistics in Medicine · doi:10.1002/sim.721 · Cited by 399 · cited 1×
“at random [34].”
Downey, R. J., Akhurst, T., Gonen, M., Vincent, A., Bains, M. S., Larson, S., & Rusch, V. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.109 · Cited by 358
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Piert, M., Machulla, H. ‐., Picchio, M., Reischl, G., Ziegler, S. I., Kumar, P., Wester, H.-J., Beck, R., McEwan, A. J. B., Wiebe, L. I., et al. (2005) · PubMed · Cited by 319
Hypoxia Dose Painting by Numbers: A Planning Study
Thorwarth, D., Eschmann, S.-M., Paulsen, F., & Alber, M. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.11.061 · Cited by 301 · cited 1×
“Indeed, more specific tracers, such as (18)F-misonidazol, may be useful for dose-painting within the tumour as well [37].”
BackgroundInternational Commission on Radiation Units and Measurements
(2014) · Journal of the ICRU · doi:10.1093/jicru_ndw040 · Cited by 260
Cooper, R. A., Carrington, B. M., Loncaster, J. A., Todd, S. M., Davidson, S. E., Logue, J. P., Luthra, A. D., Jones, A. P., Stratford, I., Hunter, R. D., et al. (2000) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(00)00259-0 · Cited by 210 · cited 1×
“It has become increasingly clear, that a tumour is heterogeneous for varying characteristics, possibly also for radioresistance [16,17].”
Backgroundfor the Swiss Group for Clinical Cancer Research (SAKK), B., Betticher, D. C., Hsu Schmitz, S.-F., Tötsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R. A., Pless, M., Habicht, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603075 · Cited by 207
van Baardwijk, A., Dooms, C., van Suylen, R. J., Verbeken, E., Hochstenbag, M., Dehing-Oberije, C., Rupa, D., Pastorekova, S., Stroobants, S., Buell, U., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.027 · Cited by 196
Self-citationVanderstraeten, B., Duthoy, W., Gersem, W. D., Neve, W. D., & Thierens, H. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.03.003 · Cited by 194 · cited 1×
“significant differences in perfusion, hypoxia, cell density and proliferation within the tumour [18–22].”
BackgroundStandardised FDG uptake: A prognostic factor for inoperable non-small cell lung cancer
Borst, G. R., Belderbos, J. S. A., Boellaard, R., Comans, E. F. I., Jaeger, K. D., Lammertsma, A. A., & Lebesque, J. V. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.026 · Cited by 184 · cited 2×
“FDG as a PET tracer is of particular interest in this respect because first, its maximal uptake in the tumour is prognostic for survival of patients with NSCLC, both treated with surgery or radiotherapy [24–28].”
BackgroundManus, M. M., Hicks, R., Matthews, J., Wirth, A., Rischin, D., & Ball, D. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.11.024 · Cited by 164
Functional imaging of intratumoral hypoxia
Foo, S. S., Abbott, D. F., Lawrentschuk, N., & Scott, A. M. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.06.007 · Cited by 115 · cited 1×
“significant differences in perfusion, hypoxia, cell density and proliferation within the tumour [18–22].”
BackgroundGarrido, P., González-Larriba, J. L., Insa, A., Provencio, M., Torres, A., Isla, D., Sánchez, J. M., Cardenal, F., Dómine, M., Barcelo, J. R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0014 · Cited by 112 · cited 1×
“Although the prognosis has improved, in locally advanced non-small cell lung cancer (NSCLC), the 5-year survival is 20% at best [2–7].”
BackgroundEschmann, S. M., Friedel, G., Paulsen, F., Reimold, M., Hehr, T., Budach, W., Scheiderbauer, J., Machulla, H.-J., Dittmann, H., Vonthein, R., et al. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1953-2 · Cited by 91 · cited 2×
“FDG as a PET tracer is of particular interest in this respect because first, its maximal uptake in the tumour is prognostic for survival of patients with NSCLC, both treated with surgery or radiotherapy [24–28].”
BackgroundRadiotherapy Adapted to Spatial and Temporal Variability in Tumor Hypoxia
Søvik, Å., Malinen, E., Skogmo, H. K., Bentzen, S. M., Bruland, Ø. S., & Olsen, D. R. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.027 · Cited by 81 · cited 1×
“There is a growing interest in radiation oncology to selectively target radio-resistant areas with a high probability of persisting tumour cells after treatment within the tumour [18,35,36].”
Backgroundvan Baardwijk, A. A. W., Bosmans, G., Boersma, L. J., Wanders, S. L., Dekker, A. L. A. J., Dingemans, A. C., Bootsma, G. P., Geraedts, W. H., Pitz, C. C. M., Simons, J., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.070 · Cited by 71 · cited 1×
“For each patient, the radiation dose was escalated to an individualized maximal total tumour dose, applying an MLD of 19 Gy while respecting a maximum spinal cord dose of 54 Gy [14].”
MethodSelf-citationBentzen, S. M. (2007) · Cancer treatment and research · doi:10.1007/978-0-387-36744-6_3 · Cited by 50 · cited 1×
“There is a growing interest in radiation oncology to selectively target radio-resistant areas with a high probability of persisting tumour cells after treatment within the tumour [18,35,36].”
Background
Cited by
Image-guided radiotherapy: from current concept to future perspectives
Jaffray, D. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.194 · Cited by 496
Predicting outcomes in radiation oncology—multifactorial decision support systems
Lambin, P., van Stiphout, R. G. P. M., Starmans, M. H. W., Rios-Velazquez, E., Nalbantov, G., Aerts, H. J. W. L., Roelofs, E., van Elmpt, W., Boutros, P. C., Granone, P., et al. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.196 · Cited by 402
Self-citationTargeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
Salem, A., Asselin, M.-C., Reymen, B., Jackson, A., Lambin, P., West, C. M. L., O’Connor, J. P. B., & Faivre-Finn, C. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx160 · Cited by 266
Self-citationRios Velazquez, E., Aerts, H. J. W. L., Gu, Y., Goldgof, D. B., De Ruysscher, D., Dekker, A., Korn, R., Gillies, R. J., & Lambin, P. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.09.023 · Cited by 120
Self-citationDosani, M., Yang, R., McLay, M., Wilson, D., Liu, M., Yong-Hing, C. J., Hamm, J., Lund, C. R., Olson, R., & Schellenberg, D. (2019) · Current Oncology · doi:10.3747/co.26.4167 · Cited by 28
Metadata
- Authors
- Aerts, H. J. W. L., van Baardwijk, A. A. W., Petit, S. F., Offermann, C., Loon, J. V., Houben, R., Dingemans, A.-M. C., Wanders, R., Boersma, L., Borger, J., Bootsma, G., Geraedts, W., Pitz, C., Simons, J., Wouters, B. G., Oellers, M., Lambin, P., Bosmans, G., Dekker, A. L. A. J., & Ruysscher, D. D.
- Venue
- Radiotherapy and Oncology
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 91
- Issue
- 3
- Pages
- 386-392
- ISSN
- 0167-8140 (ISSN-L)
- OpenAlex
- W2028760979
- Cited by
- 186
- References
- 26
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.